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Abstract
Introduction Despite advances in infection prevention
and control, catheter-associated urinary tract infections
(CAUTIs) are common and remain problematic. A number
of measures can be taken to reduce the risk of CAUTI
in hospitals. Appropriate urinary catheter insertion
procedures are one such method. Reducing bacterial
colonisation around the meatal or urethral area has
the potential to reduce CAUTI risk. However, evidence
about the best antiseptic solutions for meatal cleaning
is mixed, resulting in conflicting recommendations
in guidelines internationally. This paper presents the
protocol for a study to evaluate the effectiveness
(objective 1) and cost-effectiveness (objective 2) of
using chlorhexidine in meatal cleaning prior to catheter
insertion, in reducing catheter-associated asymptomatic
bacteriuria and CAUTI.
Methods and analysis A stepped wedge randomised
controlled trial will be undertaken in three large Australian
hospitals over a 32-week period. The intervention in
this study is the use of chlorhexidine (0.1%) solution for
meatal cleaning prior to catheter insertion. During the
first 8 weeks of the study, no hospital will receive the
intervention. After 8 weeks, one hospital will cross over to
the intervention with the other two participating hospitals
crossing over to the intervention at 8-week intervals
respectively based on randomisation. All sites complete
the trial at the same time in 2018. The primary outcomes
for objective 1 (effectiveness) are the number of cases of
CAUTI and catheter-associated asymptomatic bacteriuria
per 100 catheter days will be analysed separately using
Poisson regression. The primary outcome for objective
2 (cost-effectiveness) is the changes in costs relative to
health benefits (incremental cost-effectiveness ratio) from
adoption of the intervention.
Dissemination Results will be disseminated via
peer-reviewed journals and presentations at relevant
conferences.A dissemination plan it being developed.
Results will be published in the peer review literature,
presented at relevant conferences and communicated via
professional networks.
Ethics Ethics approval has been obtained.
Trial registration number 12617000373370, approved
13/03/2017. Protocol version 1.1.

Strengths and limitations of this study
►► Randomised control design
►► Evaluation of effectiveness and cost-effectiveness
►► Limited to hospitals in high-income country

Introduction
Indwelling urinary catheters are commonly
used in healthcare facilities, with foundation work indicating that 26% of patients
admitted to an Australian hospital receive an
indwelling urinary catheter and 1% of these
patients develop catheter-associated urinary
tract infections (CAUTIs).1CAUTIs have
been associated with increased morbidity,
mortality, increased length of stay in hospital
and higher hospital costs for patients and
health systems.2 Data from the International
Nosocomial Infection Control Consortium
(INICC) surveillance study, conducted in 703
intensive care units in low and middle-income
countries, suggest the incidence of CAUTI
to be 4.8 per 1000 device days (years 2010–
2015).3 In Australia, an estimated 380 000 bed
days are lost each year due to healthcare-associated urinary tract infections (UTIs), a large
proportion of which are CAUTIs. CAUTIs are
also associated with higher risk of antimicrobial resistance (AMR), making the treatment
of patients difficult.4 5AMR in UTIs has also
been shown to be increasing globally, further
emphasising the need to develop interventions to reduce the incidence of CAUTIs.6
Studies have shown that the incidence
of CAUTI can be reduced.7 8 Nonetheless,
despite some advances in infection prevention and control, CAUTIs remain problematic.9 Evidence shows that reducing
bacterial colonisation around the meatal
or urethral area has the potential to reduce
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CAUTI risk.10 However, evidence about the best antiseptic solutions for meatal cleaning is mixed. Previous
research also identified a lack of documentation and
knowledge in relation to the meatal cleaning solution
used prior to catheter insertion.1 Unsurprisingly, there
is variation in practice within Australian hospitals with
respect to catheter insertion, and specifically the agent
used to clean the meatal area prior to insertion. These
issues provided a strong rationale for the study investigators to conduct a systematic review and meta-analysis
of published literature, investigating the effectiveness
of antiseptic cleaning during urinary catheter insertion
for the prevention of CAUTI.11 This review of current
research knowledge identified the need for a well-designed intervention study as well as a limited number
of studies evaluating the cost-effectiveness of using an
antiseptic during catheter insertion. As health budgets
are finite, clinical practice needs to use cost-effective
strategies. The cost of chlorhexidine 0.1% solution is
considerably higher than 0.9% normal saline.
Given the importance of meatal colonisation in the
pathogenesis of CAUTIs, emerging AMR, the frequency
with which catheters are used and the burden of CAUTIs
in Australia and in hospital settings worldwide, the generation of evidence using a high-quality randomised trial is
needed to determine the efficacy and cost-effectiveness
of meatal cleaning. This will inform infection prevention and control practice and policy in Australia and
internationally.
Trial objectives
The trial objectives listed below pertain to both the
cluster and individual level. The trial is registered with
the Australia New Zealand Clinical Trial Registry (No
12617000373370).
Objective 1
The first objective is to evaluate the effectiveness of using
chlorhexidine in meatal cleaning prior to catheter insertion, in reducing catheter-associated asymptomatic bacteriuria (CA-ASB) and CAUTI.
Objective 2
The second objective is to estimate the cost-effectiveness
of the decision to adopt chlorhexidine in meatal cleaning
prior to catheter insertion.

Figure 1
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Methods
Study design
A stepped wedge randomised controlled trial will be
undertaken in three large hospitals over a 32-week period
(example trial timing are in figure 1). The stepped wedge
design includes an initial period where no hospitals are
exposed to the intervention.12 Afterwards, at 8-week
intervals (the ‘steps’) each hospital sequentially crosses
over from the control to the intervention until all hospitals are exposed to the intervention for the final 8 weeks
until conclusion in week 32. The study design enables
each hospital to act as its own control, which removes
the potential for some confounders such as variations
in hospital size and case mix and differences between
public and private hospitals. Staggered commencement
and duration of the intervention supports feasibility while
maintaining the rigour of the study.13 This design will also
allow research staff to work with individual hospitals as
they change over, maximising consistency of intervention
and aiding implementation.13 In addition, data collection continues throughout the study, so that each cluster
contributes observations under both control and intervention observation periods.
Study population
Three Australian hospitals that fulfil the eligibility criteria
will be enrolled in the study. These criteria are as follows:
1. Has an intensive care unit
2. Be classified by the Australian Institute of Health and
Welfare as a principal referral hospital OR a public
acute group A hospital (with more than 400 beds),
OR in the case of a private hospital has 400 inpatient
beds OR has more than 30 000 patient admissions per
year.
Other considerations
Hospitals could be excluded from the study if within the
study time frame they are
1. undertaking a project that may influence the outcomes
measured in this study
2. opening, closing or relocating.
Areas of hospital and patient-level inclusion and exclusion criteria
The study will be a hospital wide study, but will exclude
patients with indwelling urinary catheters within a

Study design overview. Blue, control; green, intervention.
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hospital that are not considered appropriate for the intervention, for example neonatal intensive care. Patients
<2 years old, with an allergy, contraindication or other
medical reason preventing the use of the intervention
for cleaning the urethral meatal area will be excluded.
Patients who require in-and-out or suprapubic catheterisation will also be excluded as well as those with symptoms
and signs suggestive of UTI and patients already undergoing treatment for UTI. All data from any patient lost to
follow-up (postcatheter insertion) will be excluded.
Recruitment
The study team will list all eligible sites then order the
list to ensure (1) a representation of both private and
public hospitals and (2) representation from at least two
Australian states and territories. The recruitment process
will purposively select and approach eligible hospitals to
optimise the feasibility and practicality of completing the
trial.
Intervention
The intervention in this study is the use of chlorhexidine (0.1%) solution for meatal cleaning prior to catheter insertion. The control is the use of normal saline
(0.9%) for meatal cleaning. During the first 8 weeks of
the study, no hospital will receive the intervention. After
8 weeks, one hospital will cross over to the intervention
with the other two participating hospitals crossing over to
the intervention at 8-week intervals respectively based on
randomisation.
Implementing the intervention
In the week prior to the intervention commencing, information sessions about the study will be provided to participating hospitals and staff. A variety of methods will be
used to further alert staff and raise awareness about the
intervention prior to it being rolled out. These methods
include placing wall posters in wards and key hospital
locations, handing out hospital newsletters and information leaflets as well as branded promotional material,
such as pens. To avoid potential confounding, information and awareness sessions are limited to just the change
of product, not education around catheter insertion or
management practices.
Chlorhexidine 0.1% solution will be used by clinical staff
at participating hospitals for cleaning the meatal area of

patients prior to urinary catheter insertion. To aid implementation of the intervention, investigators will work with
participating hospitals and use hospital data collection
and reporting systems currently in place. This will involve
incorporation of the 0.1% chlorhexidine solution into
existing catheter procedure packs at the hospitals where
possible, visual reminders where urinary catheters are
stored and temporary amendment to hospital procedural
documentation.
As per hospital’s usual practice, details of the catheter
insertion will be documented by clinical staff. To achieve
optimal documentation of the procedure, catheter insertion stickers may be made available to hospitals for use in
patients’ medical notes.
Potential confounders
Lubricants are used during the catheter insertion process
and may contain an antiseptic. The lubricant used during
the entire study (control and intervention periods) will
remain constant in each hospital.
Randomisation and blinding
Hospitals will be randomly assigned to one of three dates
to cross over to the intervention which will occur once
every 8 weeks over the trial duration of 32 weeks. All
included hospitals will be provided with sufficient notice
of the dates to cross over to the intervention. Computer-generated randomisation of the cross over dates for the
hospitals will be performed independently by an investigator not involved in assessment or delivery of the intervention. Hospitals will not be blinded because it is not
feasible to blind staff administering the intervention. The
outcome of the randomisation process will be revealed by
the project manager to the participating hospitals prior
to the commencement of the study.
Outcomes and definitions
The outcomes for each objective are outlined in table 1.
For objective 1, the primary outcomes are the cases of
CA-ASB and CAUTI. For objective 2, the primary outcome
is the cost-effectiveness of the intervention.
Catheter-associated asymptomatic bacteriuria is defined
as the presence of ≥105 colony-forming unit (cfu)/ml
of ≥1 bacterial species in a single catheter urine specimen
in a patient without symptoms compatible with UTI.14

Table 1 Key outcome measures
Objective 1
Effectiveness of using chlorhexidine in
meatal cleaning prior to catheter insertion
Objective 2
Cost-effectiveness of the intervention

Primary outcome
Secondary outcome
Primary outcome

The number of cases of CA-ASB per 100 catheter days
The number of cases of CAUTI per 100 catheter days
The number of BSIs associated with a UTI
Changes in costs relative to health benefits (incremental
cost-effectiveness ratio) from adoption of the intervention
Changes in costs associated with implementing the
intervention relative to the change in QALYs

BSI, blood stream infection; CA-ASB, catheter-associated asymptomatic bacteriuria; CAUTI, catheter-associated urinary tract infection; QALY,
quality-adjusted life years; UTI, urinary tract infection.
Mitchell BG, et al. BMJ Open 2017;7:e018871. doi:10.1136/bmjopen-2017-018871
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Catheter-associated urinary tract infection is defined
according to the National Healthcare Safety Network
criteria.15 16 A patient must meet all three criteria below:
1. Patient had an indwelling urinary catheter that had
been in place for >2 days on the date of event (day of
device placement=day 1) AND was either present for
any portion of the calendar day on the date of event
or removed the day before the date of event.
2. Patient has at least one of the following signs or symptoms: fever (>38.0°C); suprapubic tenderness; costovertebral angle pain or tenderness; urinary urgency;
urinary frequency; dysuria.
3. Patient has a urine culture with no more than two
species of organisms identified, at least one of which
is a bacterium of ≥105 cfu/mL.
Blood stream infection (BSI) associated with a UTI is
defined according to National Healthcare Safety Network
criteria.15 A patient must meet the definition for CAUTI
and has at least one organism from the blood specimen
that matches an organism identified in the urine specimen that is used as an element to meet the CAUTI criterion. The blood specimen must be collected during the
secondary BSI attribution period when the urinary catheter is in place.
Data collection
Data will be collected by a specific staff member or
members at the hospital, with the support of the research
team. The research team will provide the hospital staff
member(s) with training about the project, data collection and submission process and data collection tools.
For the purpose this paper, the dedicated hospital staff

Figure 2
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member(s) will be referred to as hospital personnel.
Figure 2 summarises the data collection process.
Hospital personnel will prospectively collect data 3 days
a week at each hospital during both control and intervention periods. Patients who receive an indwelling urinary
catheter will be identified and followed-up during the
trial period (for a period of 7 days postcatheter insertion,
discharge or 48 hours postcatheter removal—whichever
occurs first). Medical notes of patients will be reviewed
to obtain demographic and clinical data such as hospital
number, age, sex, date of admission, signs or symptoms of
UTI. Co-morbidity data will be collected where possible.
Details of catheter insertion specifically date and time of
insertion, designation of person inserting catheter, catheter type and catheter size will also be obtained from the
patients’ medical notes (where documented). If the insertion date is not documented, the patient will be excluded
from the study. Denominator data on the number of catheter days over the trial period will be collected at each
hospital during both control and intervention periods.
The number of catheter days for each patient included in
the study will be estimated from the date of catheter insertion and date of removal. Hospital personnel will record
all captured data in a spreadsheet designed specifically
for the purpose of the trial.
Information for the primary (CA-ASB and CAUTI)
and secondary (BSI) outcome measures will be collected
from the microbiology laboratory database of participating hospitals. Results of all positive urine cultures
either attributable to bacteriuria or true UTI as well as
positive blood cultures are registered in hospital microbiology laboratory databases. Hospital personnel will

Overview of data collection process.
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obtain weekly reports from the microbiology laboratory
of participating hospitals to identify the outcomes. The
patient record number will be used to link demographic
and clinical data of patients with a urinary catheter to
microbiology laboratory data. To differentiate between
CA-ASB and CAUTI, additional data on symptoms and
signs of UTI will be collected from patients’ medical
notes by research assistants.
Information to inform changes to total costs and health
benefits from a decision to adopt the intervention will
be obtained. Changes to costs will include the resources
required to implement the intervention and the changes
to use of health services. Changes to health benefits
will be captured by estimating quality-adjusted life years
(QALY) outcomes. Hospital personnel will prospectively
obtain monthly data from each participating hospital on
the cost of purchasing resources, such as catheter procedure packs, used for implementing the intervention.
Hospital personnel will also obtain data on antimicrobial
use for patients, specifically the name, dose and duration of antimicrobial, which will be used for estimating
antimicrobial therapy costs in control and intervention
periods. Hospital staff involved in the trial will be surveyed
immediately following completion of the intervention
to evaluate extra staff time spent in activities related to
planning and implementing the intervention. To calculate QALYs, primary data on age obtained from medical
notes of patients will be used along with estimates from
the published literature.17

sample size in each hospital, a hospital is to have at least
30 000 patient admissions per year.
Analysis
Objective 1: effectiveness of using chlorhexidine in meatal cleaning
prior to catheter insertion
The number of CA-ASB, CAUTI and BSI will be analysed
separately using Poisson regression, with the number of
cases as the dependent variable and number of patient
catheter days as the denominator. This denominator will
help control for changes in catheter use during the study
period. The key independent variable will be the intervention. The key outcomes will be estimated reduction
in cases of CA-ASB, CAUTI and BSI due to the intervention. The characteristics of the hospital (eg, size) will not
be independent variables as these should remain roughly
constant throughout the study observations. There is
no expected delay in the effect of intervention on the
outcome.

Power calculation
Sample size and power were calculated on the basis of
CAUTI, as it is assumed that the power to detect an incremental cost-effectiveness ratio was greater than that for
relevant clinical endpoints. The at-risk population are
those that receive a catheter while in hospital. Based on
pilot work, the estimated proportion of patients developing a CAUTI for this study is 3.4%.1 We estimate a
20% reduction using a Cohen’s d size effect measure
at 0.2 (small effect). Based on individual randomisation of two groups (control and intervention), power of
80%, alpha of 0.05%, effect size of 0.2 and two-sided test
for comparison of two means were estimated. As this
is a stepped wedge design, we have used a sample size
formula from Hussey and Hughes and operationalised
the design effect from Hemming.12 18 For the design
effect, we have assumed three hospitals, three time
periods, with N1 being the sample size of 784. Three
different scenarios were modelled, each with different
intracluster correlation coefficients—0.1, 0.05, 0.01.
An intracluster correlation coefficient of 0.05 was
subsequently determined and the sample size (m=220,
M=880) for each cluster.
Pilot work identified that 26% of patients admitted to
hospital in Australia receive a urinary catheter.1 19 As we
are excluding patients who had a catheter inserted in
theatre, we estimated that 5% of admitted patients receive
a catheter not inserted in theatre. To obtain the required

Objective 2: cost-effectiveness of the intervention
The effectiveness data from objective 1 will be a key
parameter in the cost-effectiveness model. Final outcomes
for the cost-effectiveness evaluation are the incremental
cost-effectiveness ratio estimated as the cost per QALY
gained, and the changes to costs in QALYs. Published
guidelines for costing an intervention will be followed.20
The changes to costs from adopting the intervention
will be estimated by the extra staff time spent both planning and implementing the intervention, converted to a
dollar figure using full employment costs. Other costs are
product costs. These cost data will be collected prospectively on a monthly basis for product costs and a survey
immediately after the intervention is implemented (staff
costs). Quantities of resources will be standardised to
all hospitals to ensure valid comparison of costs across
all sites. This will reduce uncertainty in estimates which
often results from using retrospective administrative data.
The major cost savings from reducing infections are characterised by the bed days saved from keeping patients infection free and hence discharging them earlier. The reasoning
is that 90% of the costs of hospital services are fixed so bed
days saved are an appropriate currency. Data from a previous
study using multistate modelling to estimate the extra length
of stay per case of urinary bacteriuria will be used in the
model.21 Other cost savings are averted laboratory diagnosis
costs and antimicrobial therapy costs, estimated by counting
the frequency of laboratory tests and antimicrobial therapy
costs in the control and intervention periods. These will be
collected prospectively as part of the data collection process.
Laboratory costs using the relevant medical benefit scheme
item costs will be used. For antimicrobial therapy costs, pharmaceutical benefits scheme costs will be used.
Changes to health benefits will be informed by the extra
death risk due to infection. This parameter will come from
a previously described analysis of mortality associated with
urinary bacteriuria. These estimates used multistate models
that avoid time and length biases to estimate increases in
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mortality attributable to infection. The results are HRs that
can be used to predict reduction in deaths from avoided
infections. The mean age of hospital patients will be used
to predict years of life gained and preference-based utility
scores will be used to weight life expectancy, allowing us to
calculate QALYs. We will not collect primary data on preference-based utility scores. Instead, these estimates will be
taken from the published literature.22
The change to total costs at the hospital level will be estimated by summing intervention costs and deducting cost
savings from reduced lengths of stay and use of healthcare
resources that arise from reduced incidences of infection.
The changes to health benefits will be estimated in QALYs
using the number of life years saved from reduced infection
outcomes; the expected duration of life (had infection not
occurred) based on age and data from the published literature.17 All costs and health benefits arising in future periods
will be appropriately discounted. Uncertainties in parameter estimates will be captured using appropriate statistical
distributions to describe the variability. For example, the
beta distribution would be a good choice for infection risk
as this distribution is restricted to interval 0–1. The parameters of the beta distribution will be chosen to reflect what
we know about the mean and range in infection risk (eg,
a beta distribution with a mean rate of infection of 0.003%
and 95% CI of 0.001 to 0.005). The fitted distributions will
be subject to random re-samples simulated 10 000 times. The
distributions of all prior parameters are used to estimate the
posterior distributions of ‘change to costs’ and ‘change to
QALY’ outcomes.
The decision will be informed by plotting cost-effectiveness acceptability curves with threshold value between zero
and 100 000 per QALY gained, and using the net monetary
benefits framework.
These approaches are semi-Bayesian and appropriately
account for all parameter uncertainty for the adoption
decisions.

Discussion
This study addresses an identified gap in infection control
research and practice. Despite the frequency of UTIs
associated with indwelling urinary catheter use, there are
few studies focusing on their surveillance and prevention. Aligning with the emphasis on quality and safety, this
multicentre randomised controlled trial will evaluate the
effectiveness and cost-effectiveness of an antiseptic versus
non-antiseptic meatal cleaning agent to prevent CAUTIs, a
world first. The ultimate objective is the prevention of healthcare-related CAUTIs, leading to benefits for patient safety.

is sufficiently powered to detect the effect of antiseptics in
reducing CAUTI. The inclusion of the cost-effectiveness
analysis is an additional strength of this trial as to our knowledge previous trials have not evaluated the cost-effectiveness
of an antiseptic meatal cleaning agent in reducing CAUTI.
Over the past decade, cost-effectiveness analysis has evolved
further emphasising the need to address this evidence gap.
This randomised controlled trial is also strengthened by
the use of a stepped wedged design which has been found
to be particularly useful in studies evaluating intervention
effectiveness during routine implementation such as in the
case of this study where the insertion of a urinary catheter is
considered to be part of the care of the patient.23 The study
design also enables each hospital to act as its own control,
which removes the potential for some confounders such
as variations in hospital size and case mix and differences
between public and private hospitals. Furthermore, this
study identifies best practice among current practice.
Limitations
Exclusion of patients who have indwelling urinary catheters inserted in surgical theatre has the potential to
prolong recruitment of participants given that surgical
procedures are a common indication for urinary catheter insertion.24 25 However, recruitment of these patients
was not deemed feasible as it would require involvement
of all surgeons including theatre staff in the study. Unless
the participating hospital can achieve implementation in
theatre, patients who have catheters inserted in theatres will
be excluded. The initiatives taken to introduce the intervention may inadvertently improve catheter management. To
reduce this effect, no education on other aspects of catheter management (other than the product change) will be
provided to staff.
Significance
It is important that urinary catheter insertion strategies for
CAUTI prevention are supported by evidence obtained
from rigorously conducted research. This study’s significance therefore lies in its ability to inform recommendations within national infection control guidelines globally.
This study will also contribute to the development of strategies to reduce the incidence of CAUTI using cost-effective
approaches. This is even more important in the context of
finite health budgets.
Trial status
The study team is completing the recruitment of participating hospitals. The trial is due to commence in late
2017.

Strengths
Few randomised controlled trials have investigated the
effectiveness of antiseptics on CAUTI incidence during
urinary catheter insertion, and previous research has been
limited mainly due to the lack of an appropriate sample
size to demonstrate any possible beneficial effect from the
use of antiseptics.11 Our study uses a rigorous approach and

Data quality
Data will be stored in electronically in a secure (password
protected) location, by chief investigator BM at Avondale
College of Higher Education. Data quality will be enhanced
by the provision of adata collection form, quality checks by
the project manager. A data collection guide has been developed to aide and document this process. Data monitoring
will be overseen by chief investigator BM and the data
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monitoring committee consists of all chief investigators on
the study. Any approved changes to the study protocol will
be updated in Australia New Zealand Clinical Trial Registry
Access to data
Chief investigator BM will hold data during and after
study completion
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